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Abstract
Purpose Regadenoson was approved for clinical use in
Europe in 2011. Since then, it has become the default form
of stress at our institution. We have assessed the side-effect
profile and tolerability of regadenoson in patients undergoing
clinically indicated myocardial perfusion scintigraphy be-
tween July 2011 and July 2012.
Methods Clinical, stress and imaging data were recorded pro-
spectively. Symptoms during stress were recorded and defined
as mild, moderate or severe. An adverse event was defined as
any symptom that persisted for more than 30 min or that
required investigation or treatment.
Results Of 1,764 consecutive patients, 1,581 (90 %) received
regadenoson combined with submaximal exercise unless con-
traindicated. Symptoms were common (63 %) but transient
and well-tolerated. The severity of symptoms was recorded in
most patients as mild (84 %). Dyspnoea (36 %) and chest
discomfort (12 %) were the commonest side effects. Adverse
events were reported in eight patients (0.5 %), thought to be
vasovagal in seven of these. All patients recovered fully
without sequelae. There were no deaths, myocardial infarction
or hospital admissions. Regadenoson stress was performed in
206 patients (12 %) with asthma or chronic obstructive pul-
monary disease (COPD) without bronchospasm or any other
major side effect.
Conclusion We studied the symptom profile of regadenoson
in the largest European cohort to date. Regadenoson com-
bined with submaximal exercise was well tolerated, notably
also in patients with asthma or COPD. The majority of
regadenoson-related adverse events were vasovagal episodes
without sequelae.
Keywords Myocardial perfusion scintigraphy .
Regadenoson . Side effects . Safety . Tolerability
Introduction
Although dynamic exercise is the preferred form of stress for
myocardial perfusion scintigraphy (MPS), many patients are
unable to exercise maximally and pharmacological stress is
common [1]. At our institution, pharmacological stress is the
default form of stress because most patients have already been
considered for or have undergone an exercise ECG. An effi-
cient and effective way of stressing coronary function in this
setting is with the use of vasodilators. Adenosine and
dipyridamole are both potent primary coronary vasodilators
with a nonselective action, which explains the side effects
commonly associated with these agents [2–9]. To avoid side
effects and potential adverse events, a number of selective
adenosine A2A receptor agonists have been developed
[10–14]. Of these, regadenoson is the only one approved for
clinical use by the Food and Drug Administration. Approval
was granted by the European Medicines Agency in 2010 and
by the Royal Brompton & Harefield NHS Foundation Trust
New Drugs and Clinical Guidelines Committee in May 2011.
Since July 2011, we have used regadenoson as the default
form of stress, and we now have the largest experience outside
North America. The main objective of this study was to assess
the side effect profile, safety and tolerability of regadenoson in
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patients undergoing clinically indicated MPS. A secondary
objective of the study was to compare this experience with
other forms of cardiac stress.
Methods
Patient selection
Regadenoson stress was implemented at our institution on 22
July 2011. As part of an audit of clinical practice, we studied
all patients who underwent clinically indicated MPS over the
following 12 months. Clinical and imaging data were collect-
ed prospectively and retrieved for retrospective analysis from
a dedicated database. The selection of stress agent was a
clinical decision based upon using regadenoson by default
with patients receiving another form of stress if this was
preferred over regadenoson or there was a contraindication
to the use of this agent (Fig. 1). Hence, in patients with
suspected myocardial bridging, coronary anomaly or micro-
vascular dysfunction as the primary cause of symptoms, dy-
namic exercise was the preferred form of stress. Patients who
were suitable for vasodilator stress but self-reported caffeine
consumption within 12 h of the test were given high-dose
adenosine (210 μg/kg/min) to overcome the antagonism me-
diated by caffeine on the adenosine receptors [15]. Patients
with a contraindication to vasodilator stress received dobuta-
mine. After 3 months, regadenoson was given to patients with
obstructive airways disease irrespective of disease severity.
Symptoms and adverse events
Symptoms during stress were recorded and defined as mild,
moderate or severe by the health professional (a clinical nurse
specialist or a nuclear cardiologist) conducting the stress test.
A mild symptom did not distress the patient, a moderate
symptom did distress the patient but was self-limiting without
the need for intervention, and a severe symptom distressed the
patient and required some form of intervention to alleviate
it. An adverse event was defined as any symptom that
persisted for more than 30 min or that required investiga-
tion or treatment, for instance reversal of the stress agent by
aminophylline.
Stress MPS
Regadenoson was administered intravenously as a rapid injec-
tion of 400 μg over at least 10 s followed by a 5-ml saline flush.
The radiopharmaceutical was administered intravenously ap-
proximately 20 s after regadenoson injection. Unless there was
left bundle branch block or paced rhythm, regadenoson was
combinedwith bicycle exercise at 0W (free wheel), or 5, 10, 15
or 25 W depending on exercise tolerance. Supplemental exer-
cise was initiated 1 min before regadenoson injection and
continued for 2 – 3 min after injection of regadenoson. ECG
rhythm was monitored throughout and heart rate and blood
pressure recorded every 2 min or more often if necessary until
completion of the test. Patients with airways disease had
regadenoson without pretreatment with a bronchodilator. To
antagonize the effect of caffeine in patients who self-reported
caffeine ingestion within 12 h before the test, adenosine
was infused at a high dose of 210 μg/kg/min over 6 min
with supplemental exercise. Dobutamine was given intra-
venously at incremental doses of 5 – 10 μg/kg/min every
3 – 5 min starting at 5 – 10 μg/kg/min up to a maximal dose
of 40 μg/kg/min. Dynamic exercise was performed on a
bicycle ergometer at increasing workloads of 25 – 50Wevery
2 – 3 min until ≥85 % of maximum predicted heart rate was
reached or angina and ischaemic ECG changes developed.
Imaging analysis
All images were interpreted according to routine clinical prac-
tice by an experienced nuclear cardiologist. For the purpose of
Fig. 1 Flow diagram showing
patient selection for stress testing
according to routine clinical
practice
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this study, further analysis was conducted in patients who
experienced an adverse event following regadenoson injection.
Quantitative perfusion SPECT software (QPS, version 2008;
Cedars-Sinai Medical Center, Los Angeles, CA) was used to
calculate the total burden of ischaemia as the total perfusion
deficit (TPD) difference between stress and rest images. Total
ischaemic burden was defined as mild, moderate or severe if
TPDwas <6%, 6 – 9% or ≥10%, respectively. In addition, the
stress and rest summed segmental scores were calculated using
a 17-segment model with each segment scored from 0 to 4
(0 normal, 1 mild, 2 moderate, 3 severe defect and 4 absent
tracer uptake). The extent and severity of ischaemia was
defined as the difference between summed stress and summed
rest scores (SDS). A SDS <6 was considered mild, 7 – 12
moderate and >12 severe [16]. Left ventricular ejection frac-
tion was computed using Quantitative Gated SPECT software
(QGS, version 2008; Cedars-Sinai Medical Center).
Statistical analysis
Data summary and statistical comparisons were performed
using Microsoft Excel Analysis Toolpak and SPSS (IBM
SPSS Statistics v20). Continuous variables were compared
using analysis of variance; categorical variables were
compared using the chi-squared test. Logistic regression
analysis was performed to examine the association be-
tween stress-induced adverse events and potential pre-
dictors of such events.
Results
Patient characteristics
A total of 1,764 consecutive patients underwent stress MPS
between 22 July 2011 and 28 July 2012. Of these, 69 % were
male; mean ± SD age was 67±11 years and mean ± SD body
mass index 28±5 kg/m2. The majority of patients (90 %)
underwent regadenoson stress while the remainder had aden-
osine (7%), dobutamine (2%) or dynamic exercise (1%). The
prevalence of cardiovascular risk factors and other character-
istics of the population are listed in Table 1. There were no
significant differences between groups except for lung dis-
ease, which was more common (83 %) in the dobutamine
group. Symptoms on presentation are shown in Table 2. Of the
1,764 patients, 73% had a history of chest pain, and in 24% of
these patients the chest pain was angina, 60 % had dyspnoea
and 9 % had a history of heart failure, but less than 1 % had
severe heart failure. Dyspnoea was more frequent in the
dobutamine group, and there was a small excess of
patients with a history of heart failure in the adenosine
and dobutamine groups.
Haemodynamic response to stress
There was a statistically significant but clinically unimportant
difference in resting blood pressure between groups (Fig. 2).
Heart rate increased by 28±17 bpm with regadenoson stress,
19±18 bpm with adenosine, 31±24 bpm with dobutamine
and 51±24 bpm with dynamic exercise (Fig. 3). There was no
significant change in blood pressure from rest to peak stress in
the regadenoson and adenosine groups, while there was a
significant reduction in the dobutamine group. The haemody-
namic response to vasodilators was modified by concurrent
dynamic exercise: median workload 25 W (0 W, 100 W) for
regadenoson vs. 15 W (0 W, 75 W) for adenosine.
Symptoms and side effects
Symptoms were common with all forms of pharmacological
stress with 63 % of patients in the regadenoson group, 75 % of
patients in the adenosine group, 46 % in the dobutamine group
and 36 % in the exercise group (P=0.001, Fig. 4a) reporting at
least one symptom. Dyspnoea (36 %) and chest discomfort
(12 %) were the commonest side effects following regadenoson
injection. Chest discomfort and flushing occurred more often
with adenosine (29 % and 25 %, respectively) than with
regadenoson (12 % and 7 %, respectively), but light-
headedness was more common with regadenoson (7 % vs. 1 %
for adenosine; Table 3). Diarrhoea was reported by 12 patients
(1 %) in the regadenoson group compared with none in the other
groups, but this difference was not statistically significance
(P=0.9). Chest discomfort and dyspnoea were the commonest
side effects in the dobutamine group while dyspnoea was the
most frequent side effect in the exercise group. The severity of
symptoms did not differ significantly between stress agents
(P=0.3) with most symptoms graded as mild: 84 %, 88 %,
82 % and 60 % in the regadenoson, adenosine, dobutamine
and exercise groups, respectively (Table 4, Fig. 4b).
Adverse events
There were no deaths, myocardial infarction or hospital admis-
sion following stress MPS. Adverse events were observed in
eight patients (0.5 %), all in the regadenoson group (Table 5).
Seven of the eight events were episodes of symptomatic hypo-
tension with inappropriate bradycardia or failure of compensa-
tory tachycardia, and they were therefore classified as vasova-
gal. One of these occurred after intravenous cannulation and
before regadenoson injection, and the others occurred between
2 and 10 min after injection. Two episodes occurred in patients
who did not exercise. Of all vasovagal events, three were
moderate and two severe; the two severe episodes progressed
to sinus arrest and asystole lasting 30 s and 10 s and requiring
CPR. Aminophylline was administered to three patients. All
patients recovered fully without sequelae. No association was
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found between the incidence of adverse events during stress
and clinical and imaging characteristics including known coro-
nary artery disease (CAD), older age (>65 years), cardiovascu-
lar risk factors and inducible ischaemia on MPS (P >0.05 for
all). In the regadenoson group, there was a significant reduction
in heart rate and systolic blood pressure during stress in patients
who experienced at least one adverse event comparedwith those
who remained free of complications (heart rate −6±18 bpm vs.
Table 1 Patient demographics and clinical characteristics
Global Adenosine Regadenoson Dobutamine Exercise P
n % n % n % n % n %
No. of patients
Total 1,764 100 130 7 1,581 90 39 2 14 1 n/a
Male 1,211 69 96 74 1,079 68 26 67 10 71 0.6
Age (years), mean ± SD 67±11 – 69±12 – 67±11 – 68±13 – 56±25 – <0.001
BMI (kg/m2), mean ± SD 28±5 – 27±5 – 28±5 – 30±8 – 27±4 – 0.01
Diabetes 411 24 29 23 369 23 12 31 1 7 0.3
Hypertension 1,300 74 96 74 1,167 74 27 69 10 71 0,9
Hyperlipidaemia 1324 76 102 78 1,189 75 24 62 9 64 0.3
Smokers 135 11 16 19 116 7 3 8 0 0 0.1
Known coronary artery disease 1023 59 80 63 921 58 17 44 5 36 0.1
Myocardial infarction 460 26 37 28 413 26 7 18 3 21 0.7
Percutaneous coronary intervention 627 36 43 33 571 36 10 26 3 21 0.4
Coronary artery bypass grafting 285 16 28 22 251 16 4 10 2 14 0.3
Lung disease 304 18 25 20 246 16 30 83 3 25 <0.001
P values are between stress groups (statistical significance at P<0.05)
Table 2 Clinical history and presenting symptoms
Global Adenosine Regadenoson Dobutamine Exercise P
n % n % n % n % n %
Chest discomfort
None 475 27 29 22 431 27 9 23 5 36 >0.5
Non-anginal 8 0 0 0 8 1 0 0 0 0
Atypical chest pain 641 36 46 35 572 36 15 38 6 43
Angina 430 24 34 26 388 25 10 26 1 7
CCS 1 274 66 22 69 244 65 7 64 1 100
CCS 2 99 24 4 13 91 24 4 36 0 0
CCS 3 42 10 6 19 39 10 0 0 0 0
CCS 4 0 0 0 0 0 0 0 0 0 0
Nonspecified chest pain 209 12 21 16 181 11 5 13 2 14
Heart failure 137 9 20 17 110 8 6 21 1 8 0.002
NYHA 1 51 3 5 4 43 3 2 7 1 8
NYHA 2 40 3 5 4 32 2 3 11 0 0
NYHA 3 41 3 10 8 31 2 0 0 0 0
NYHA 4 5 0 0 0 4 0 1 4 0 0
Dyspnoea 1,041 60 87 70 915 59 33 89 6 43 0.001
Mild 637 37 43 34 583 37 9 24 2 14
Moderate 332 19 35 28 273 18 21 57 3 21
Severe 72 4 9 7 59 4 3 8 1 7
CCS Canadian Cardiovascular Society angina class, NYHA New York Heart Association heart failure class
Statistical significance at P<0.05
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28±16 bpm, P =0.001; and systolic blood pressure −36±
34 mmHg vs. 5±26 mmHg, P =0.01). Only heart rate and
systolic blood pressure reduction during stress predicted the
likelihood of an adverse event after regadenoson injection
(P>0.01 for both).
Lung disease
Lung disease including airways obstruction was documented
by clinical history in 297 patients (17 %) of whom 145 (49 %)
had asthma, 111 (37 %) chronic obstructive pulmonary dis-
ease (COPD), 34 (11 %) interstitial lung disease and 7 (2 %)
bronchiectasis. Of these 297 patients, 242 (81 %) received
regadenoson. Of all patients with a history of asthma in the
regadenoson group, 71 % had intermittent symptoms, 26 %
mild persistent symptoms, and 3 % moderate symptoms, and
none had severe persistent asthma. No patient developed
bronchospasm with regadenoson, but one patient (male,
79 years old) with a history of previous myocardial infarction
(MI) but not known to have airways disease developed mild
bronchospasm. The bronchospasm developed soon after
Fig. 3 Heart rate at baseline and peak stress. Baseline measures were
obtained immediately before starting the stress test. Peak heart rate was
that with the largest change over the duration of the test. Values are means
± 2 standard deviation
Fig. 2 Blood pressure response to stress. a Baseline and peak systolic
blood pressure; b baseline and peak diastolic blood pressure. Baseline
measures were obtained immediately before starting the stress test. Peak
blood pressure was that with the largest change over the duration of the
test. Values are means ± 1 standard deviation
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injection of regadenoson and resolved shortly after inhalation
of salbutamol. Most patients in the dobutamine group (77 %)
had some form of lung disease, mainly asthma or COPD. Of
these, 13 % had intermittent asthma, 19 % mild persistent
asthma, 44 % moderate persistent asthma and 15 % severe
persistent asthma. None of the patients who underwent dobu-
tamine stress experienced any respiratory complications.
Imaging results
A total of 673 MPS studies (38 %) were normal. Among
abnormal scans, a reversible or inducible myocardial perfu-
sion abnormality was present in 946 (54 %). A representative
patient is shown in Fig. 5. Of these, 366 (21 %) studies
showed an additional fixed abnormality consistent with myo-
cardial damage (full- or partial-thickness infarction). No in-
ducible ischaemia but evidence of infarction was observed in
the remaining 141 patients (8 %). Four studies were consid-
ered non-diagnostic (0.2 %). Among patients who experi-
enced at least one stress-related adverse event (n =8), mild to
moderate inducible ischaemia was present in 5 of 7 MPS
studies; none of the studies showed severe ischaemia or severe
left ventricular dysfunction on ECG-gated images (Table 5).
In one patient with severe vasovagal response, imaging was
delayed >45 min post-thallium injection and hence no stress
images were obtained.
Discussion
This report summarizes our first year of experience
performing regadenoson stress in patients with suspected or
known CAD. To the best of our knowledge, this is the largest
series of patients undergoing clinically indicated regadenoson
MPS in Europe. These results confirm previous observations
and show that regadenoson in this setting is well tolerated and
safe with no deaths, hard cardiac events or hospital admission
following its administration. The rate of other untoward
events was 0.5 % and these were mainly vasovagal episodes
that resolved without sequelae, although two patients received
CPR as part of medical management.
Our results are very similar to those of previous studies
including the phase III ADVANCE clinical trials. In these
studies, side effects were reported in slightly over 70 % of
Fig. 4 Symptoms during stress:
a frequency; b severity. *P ≤0.05
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patients undergoing regadenoson stress [17, 18]. In the current
study, just over 60 % of patients experienced at least one side
effect following regadenoson injection. The lower frequency
of side effects in the current study might be explained by the
addition of submaximal exercise, which is known to reduce
the frequency and severity of vasodilator-related side effects
[19]. As in previous studies [17, 18], most side effects were
mild and well tolerated. We have also previously shown that
side effects are less common with increasing BMI, although
this aspect was not assessed in the study [20].
As shown by previous comparisons between regadenoson
and adenosine stress, the frequency and intensity of side effects
after regadenoson injection is similar to that of adenosine, but
the nature and quality of side effects differs between the two
agents; for example, chest discomfort and flushing are more
common with adenosine than regadenoson, while headache
and gastrointestinal symptoms are more frequent with
regadenoson [17, 18]. Differences in the degree of vasodilation
and sympathetic stimulation as well as differences in affinity
for the adenosine receptors may account for this finding [21].
Gastrointestinal symptoms and especially diarrhoea have
the potential for causing procedural delays that may compro-
mise image quality and accuracy, particularly when 201Tl is
used. Nearly 1 % of our patients had diarrhoea following
regadenoson injection; however, all episodes were self-
limiting and images were obtained in all patients. The fre-
quency of diarrhoea in our series was significantly lower than
the 11 % found in a recent study [22]. It is possible that lack of
awareness of causality between regadenoson and gastrointes-
tinal symptoms and cultural differences might have prevented
our patients from reporting this unpleasant side effect.
However, it is also likely that the addition of dynamic exercise
might have contributed to the lower frequency of gastrointes-
tinal symptoms. Indeed, Thomas et al. have already shown
that regadenoson combined with exercise is associated with a
low frequency of gastrointestinal symptoms (5 %) [23].
Regadenoson was safe with no fatal or nonfatal cardiac
events observed in the hours following its administration (up
to 4 h after the procedure). There was no need for hospital
admission following regadenoson stress and this is consistent
with previous observations [17, 18]. No association was found
between the incidence of adverse events and several clinical
and imaging parameters. In contrast to previous reports, most
untoward adverse events were episodes of symptomatic hypo-
tension associated with absolute or relative bradycardia follow-
ing regadenoson injection [17]. To the best of our knowledge
no vasovagal episodes have been described before [18].
It is beyond the scope of this report to explain the mecha-
nism of action by which regadenoson might cause vasovagal
syncope but we can hypothesize. In general, some individuals
are prone to experiencing vasovagal episodes secondary to
any investigation [24–26]. In one patient, vasovagal symp-
toms and signs developed soon after cannulation and before
regadenoson was given. All other episodes occurred after
regadenoson injection. A direct bradycardic effect of
regadenoson seems unlikely. Regadenoson has little if any
effect on the sinoatrial and atrioventricular nodes as demon-
strated in previous animal models [27]. As expected, the
incidence of bradyarrhythmias including advanced degrees
of atrioventricular block after regadenoson administration is
low [22]. Experimental studies have demonstrated that
Table 4 Severity of symptoms
Severity Adenosine Regadenoson Dobutamine Dynamic P
n % n % n % n %
Mild 90 84 939 88 14 82 3 60 0.3
Moderate 15 14 108 10 3 18 2 40
Severe 2 2 18 2 0 0 0 0
Statistical significance at P<0.05
Table 3 Symptoms and adverse
events
Statistical significance at P<0.05
Event Adenosine Regadenoson Dobutamine Dynamic P
n % n % n % n %
Any 97 75 996 63 18 46 5 36 0.001
Chest discomfort 38 29 193 12 11 28 1 7 <0.001
Palpitations 0 0 11 1 1 3 0 0 0.2
Abdominal discomfort 9 7 132 8 0 0 0 0 0.2
Nausea/vomiting 2 2 56 4 1 3 0 0 0.7
Diarrhoea 0 0 12 1 0 0 0 0 0.9
Dyspnoea 44 34 565 36 7 18 4 29 0.1
Flushing 32 25 114 7 0 0 0 0 <0.001
Light-headedness 1 1 114 7 2 5 0 0 0.1
Headache 4 3 86 5 1 3 0 0 0.8
Fatigue 4 3 17 1 0 0 0 0 0.5
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regadenoson has no significant A2B activity, and hence it
should not cause peripheral vasodilation, although there may
be some vasodilation mediated by peripheral A2A receptors.
This, however, would result in sympathetic activation with
tachycardia through the baroreceptor reflex. Two of the pa-
tients with a vasovagal episode had abdominal discomfort,
nausea or vomiting before hypotension and bradycardia.
Susceptible patients may have indirect vagal stimulation in
response to these symptoms after regadenoson injection [28,
29]. This effect could have been exacerbated by the
nonfasted status of our patients. Centrally mediated brady-
cardia and hypotension may also explain the observed
adverse events. Indeed, animal studies have shown that
activation of the A2 receptors in the posterior hypothalamus
leads to bradycardia and hypotension [30]. A direct activa-
tion of A2 receptors in the human brain has not been
proved. It is possible that in susceptible individuals, a rapid
increase in sympathetic tone mediated by direct activation
of A2A receptors in the sympathetic afferent nerves may
result in reflex vagal discharge. This has already been
proposed as a potential mechanism of action in
adenosine-sensitive syncope [31].
Lung disease
Although lung disease is not a contraindication to the use of
regadenoson, we were initially cautious and used dobutamine in
patients with persistent asthma or moderate to severe COPD.
None of the patients with airways disease who underwent
regadenoson stress developed wheeze, and hence clinically sig-
nificant bronchoconstriction following regadenoson seems un-
likely. Therefore, regadenoson is a safe option in patients with
lung disease and this has been confirmed in a recent study [32].
The proportions of abnormal (62 %) and ischaemic (54 %)
scans among our patients were significantly higher than those
reported in a recent study by Rozanski et al. looking at temporal
trends in the frequency of abnormal and ischaemic MPS over
the last two decades in patients referred to Cedars-Sinai Medical
Center [33]. According to the study, there has been a progressive
decline in the prevalence of abnormal MPS studies from approx-
imately 41 % in 1991 to only 9 % in 2009. Likewise, there has
been a reduction in the prevalence of ischaemic scans from 30%
in 1999 to only 5 % in 2009. It is important to bear in mind that
for the purposes of the study, 24 % of patients were excluded
because of previous MI, mechanical revascularization, history of
Fig. 5 A 71-year-old man with chest pain of suspected cardiac origin. a
Regadenoson/rest 201Tl MPS. The left ventricular tomograms and the
corresponding polar maps show an extensive inducible perfusion
abnormality in the left anterior descending coronary artery (LAD) terri-
tory. b , c X-ray coronary angiography demonstrates (b ) total LAD
occlusion (arrow) and (c) collateralization from the right coronary artery
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cardiomyopathy or valve disease. In contrast, our study included
all patients referred for MPS regardless of medical history.
Patients with known CAD, including those with previous MI
or revascularization, comprised over half of our population. Our
patients were on average 10 years older, with more cardiovascu-
lar risk factors and a higher frequency of anginal symptoms than
in the Cedars-Sinai study, and this may partly explain the higher
number of abnormal and ischaemic scans. These differences
might also explain discrepancies found between this and recent
studies on the side effect and safety profile of regadenoson,
especially regarding the frequency of hypotensive episodes. In
relative terms, our patient population was at “higher risk” of any
complications during stress and hence likely to have exhibited a
less favourable safety profile. Nonetheless, our findings indicate
that regadenoson, as well as other forms of stress, are safe in this
patient populationwith side effects and tolerability comparable to
those observed in “lower risk” patients.
Limitations
This study was observational and did not control for sample size.
Although statistical analysis was limited by the large difference
between group sizes, descriptive comparison was possible. As
mentioned above, it was not possible to explain the mechanism
of action bywhich regadenosonmight cause vasovagal episodes.
This observation is hypothesis-generating and therefore further
research is needed to elucidate the underlying mechanism(s).
Conclusion
In the largest European cohort to date, regadenoson combined
with submaximal exercise has proved to be safe and well
tolerated, notably also in patients with asthma and COPD.
Most adverse events following regadenoson injection were
vasovagal episodes. There is no clear direct mechanism by
which regadenoson might cause vasovagal syncope.
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